DOCSLIB.ORG

Hepb-Informed-Fall-2013.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

THE NEWSLETTER OF THE HEpatitiS B FOUNDatioN FaLL 2013 INSIDE THIS ISSUE: 5 Crystal Ball Raises $100,000+ No. 5 Cure Agenda at 64 Princeton Workshop 6 CHIPO: HBV and INFORMED African Immigrants 7 A Gay Man’s Thoughts on HBV Learn more about Hepatitis B Foundation’s A Nobel Challenge page 3 Research Institute Renamed in Honor of Dr. Baruch S. Blumberg HBF renames research he Hepatitis B Foundation (HBF) vaccine. (Hepatitis B is the leading tens of millions of lives.” institute the Baruch S. Blumberg Institute Thosted a grand celebration cause of primary liver cancer Established in 2004, the HBF’s in honor of its co- on October 7, 2013 for the official worldwide.) research institute has become the founder Dr. Baruch S. renaming of its research institute in The Hepatitis B Foundation nation’s leading nonprofit research Blumberg, who won honor of HBF co-founder and Nobel benefited enormously from the center with the largest concentration the Nobel Prize for his discovery of the hepatitis Laureate Dr. Baruch S. Blumberg. personal support of Dr. Blumberg. of scientists dedicated to finding a B virus. Front row L to The new Baruch S. Blumberg Institute From the very beginning, Dr. cure for hepatitis B. The research R: Mark Thompson, honors the scientific legacy of Dr. Blumberg served as the HBF’s institute is also an important president and CEO of Blumberg, who won the Nobel Prize co-founder, active member of economic driver, generating over The New York Times Co. in Medicine in 1976 for his discovery the scientific advisory board, and 250 new jobs in the past 6 years and and son-in-law of the late Dr. Blumberg; Jane of the hepatitis B virus. “Distinguished Scholar” until his fostering innovative partnerships Blumberg Thompson; Dr. Baruch Blumberg’s immense death in April 2011. that have created biotech companies Dr. Thomas London, curiosity and energy were hallmarks “This isn’t just a name change for based on new hepatitis B and cancer HBF board member; of his scientific persona. Described us; this is a sincere, motivational, therapies. Mrs. Jean Blumberg; and Dr. Timothy Block, as a pioneer and leading light in the profound statement, not just for us, Dr. Blumberg believed that the president of HBF and scientific community, Dr. Blumberg but for the entire Commonwealth of elimination of hepatitis B was entirely the Blumberg Institute. discovered the hepatitis B virus in Pennsylvania,” said HBF president possible in our lifetime. The newly (Photo by Stuart Lee 1967 and developed the blood test and co-founder Dr. Timothy Block. renamed Baruch S. Blumberg Institute Friedman, Bucks County to detect the virus, and invented the “Dr. Blumberg made one of the most name will inspire researchers to Herald, Oct. 7, 2013) first vaccine in 1969. As he predicted, important contributions to modern continue the search for a cure. it would also be the first anti-cancer medicine, which has literally saved Continued on page 3 Cause for a Cure The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide through research, education and patient advocacy. HEPATITIS B FOUNDATION From the Editor’s Desk 3805 Old Easton Road Doylestown, PA 18902 Re-energized in Our Mission Phone: (215) 489-4900 www.hepb.org [email protected] hat a difference two years make. In 2011 the Hepatitis B Foundation The Hepatitis B Foundation is a national Wcelebrated its 20th anniversary and we were ready to rest awhile on our nonprofit organization dedicated to finding a laurels after working so hard. But instead, we rallied for new challenges and now cure and improving the quality of life for those affected by hepatitis B worldwide through we have a lot to celebrate in 2013! research, education and patient advocacy. In March, the U.S. Department of Justice struck down HBV discrimination in a settlement with two New Jersey medical schools that had denied enrollment Board of Directors to students with hepatitis B. The historic ruling now officially recognizes HBV Chairman – Joel Rosen, Esq President – Timothy Block, PhD infection as a protected disability under the Americans with Disabilities Act—a Vice President – W. Thomas London, MD Joan M. Block, Co-Founder huge advocacy success in which the Hepatitis B Foundation played a key role. Treasurer – R. Donald Leedy, MBA and Executive Director To fulfill our mission of decreasing the burden of hepatitis B and liver cancer Secretary – Janine Witte in the U.S., we partnered with AAPCHO to establish Hep B United as a national program to Joan Block support local coalitions improve screening, vaccination and linkage to care, particularly among Stanley Broadbent high-risk Asian immigrants. In recognition of Hep B United’s momentum, the CDC recently Alan Brownstein, MPH awarded HBF a major grant to build the coalition and its membership, and to serve as an official Loren Danzis, Esq James Datin partner in their Know Hepatitis B national campaign (see In The News). This year we also created Deborah Faust CHIPO, the first national coalition to address the heavy burden of hepatitis B among African Anthony Ford-Hutchinson, PhD immigrants, which is an area of tremendous need David Griffith (page 6). Please give generously to our Joseph Hediger The big news in 2013, however, is the renaming Thomas Shenk, PhD of our research institute in honor of Nobel 2013 Annual Fund! Gurney Sloan, Esq Walter Tsou, MD Your donation helps us continue our Laureate Dr. Baruch S. Blumberg, who was a co- Catharine Williams founder of the HBF and mentor to many of our valuable research, outreach, and patient Executive Director – Joan Block, RN, BSN scientists and outreach professionals for almost advocacy programs. Thank you in advance for your support of our mission Scientific and Medical Advisory Board 20 years. Dr. Blumberg believed that a cure was to find a cure for hepatitis B and to Harvey Alter, MD possible in our lifetime, so we are honored to improve the lives of those affected take up the challenge with renewed energy and Timothy Block, PhD worldwide. Thank you! Carol Brosgart, MD purpose to fulfill his scientific legacy. Nathaniel Brown, MD Raymond Dwek, DPhil, FRS Anthony Ford-Hutchinson, PhD Lawrence Friedman, MD IN THE NEWS Robert Gish, MD Hie-Won Hann, MD W. Thomas London, MD Hepatitis B Foundation Receives Hep B United’s Strategic Plan William Mason, PhD Brian McMahon, MD 3-Year Grant from CDC Published in J. Community Health Kenneth Rothstein, MD Raymond Schinazi, PhD The Hepatitis B Hep B United coalition Thomas Shenk, PhD Foundation was awarded members developed the Bud Tennant, DVM a highly competitive first national community *Baruch S. Blumberg, MD, DPhil (1992-2011) Cooperative Agreement from the Centers for strategic plan to address HBF Co-Founder & Distinguished Scientist Disease Control’s Division of Viral Hepatitis hepatitis B at their first summit in 2012. to continue building a network of hepatitis The plan focuses on three areas: educating Editor – Joan Block B partners across the country through Hep providers and communities about hepatitis B Managing Editor – Anu Hosangadi B United, a national coalition established by and liver cancer; improving testing, vaccination Contact – [email protected] HBF and AAPCHO. The award will be used and linkage to care; and eliminating perinatal Copyright 2013 Hepatitis B Foundation by HBF over the next three years to support HBV transmission. The Hep B United plan Layout & Design: CP Commercial Printing Hep B United’s organizational development, aligns with the HHS Hepatitis Action Plan and B Informed is a free publication of the technical assistance and capacity building of provides specific goals to implement at the Hepatitis B Foundation with information that is provided solely for educational coalition partners that will ultimately result in local level to advance national priorities. purposes. It is not intended to serve as increased identification of people with chronic Read at hepbunited.org/wp-content/uploads/ medical advice or endorsement of any HBV infection. In addition, Hep B United will 2013/09/Hep-B-United-JCH-Sept-2013.pdf product or company. Readers should discuss all personal medical questions and decisions work closely with the CDC to distribute and Cohen C, Caballero J, Martin M, Weerasinghe I, Ninde M, Block J (Sept. 2013). Eradication of Hepatitis B: A Nationwide Community with a qualified health care provider. support their Know Hepatitis B educational Coalition Approach to Improving Vaccination, Screening, and Linkage campaign materials. to Care. Journal of Community Health;38(5):799-804. 2 Hepatitis B Foundation | B Informed | Fall 2013 hepb.org The Hepatitis B Foundation A Nobel Challenge hosted a private reception Ensuring the Scientific Legacy of Dr. Baruch S. Blumberg for the Blumberg family …continued from page 1 and friends on June 26 to announce the renaming of its research institute in honor of Nobel Laureate Dr. Baruch S. Blumberg (right) with Dr. Dr. Baruch S. Blumberg. Timothy Block, president, Hepatitis B Foundation and The event was held at United its research institute. Therapeutics, which was graciously offered by founder and CEO Dr. Martine Rothblatt. Guest speakers included “The Hepatitis B Foundation is extremely important for the field of Prof. Raymond Dwek, professor and hepatitis B. That is why I became involved. It is a major contributor and director of The Glycobiology Institute its work is critical to finding a cure. I am very committed to making sure of Oxford University; Dr. Anthony this [work] goes forward and advances,” said Dr. Baruch S. Blumberg in Fauci, director of NIAID of the National his last interview (March 2011). Institutes of Health; Dr.
Recommended publications
  • Hepatitis B: Get Tested. Get Vaccinated Booklet

    Hepatitis B: Get Tested. Get Vaccinated Booklet

    HEPATITIS B GET TESTED. GET VACCINATED. Table of Contents Hepatitis B (Hep B) and Your Liver I 1 Get Tested: Know Your Hep B Status I 5 Get Vaccinated: Protect Yourself and Others I 8 Get Care and Treatment I 8 Living with Hep B I 10 Pregnancy, Children and Hep B I 14 Information and Resources I 16 Hepatitis B (Hep B) and Your Liver Hepatitis means inflammation of the liver. Your liver keeps you healthy in many ways. It removes toxins from your body and transforms nutrients from food into energy. Hep B can cause serious health problems, including liver scarring, liver failure, liver cancer and early death. There are different types of hepatitis. Hep B is caused by the Hep B virus that infects and attacks the liver. Hep B can be prevented with a safe vaccine and can be treated to slow or stop development of serious liver damage. People living with Hep B can live a long and healthy life. 241,000 people in New York City (NYC) are living with Hep B. 2.2 million people in the United States are living with Hep B. 1 How does someone get Hep B? Hep B can be passed from one person to another through blood, semen and vaginal fluids. Some common ways to pass Hep B include: • During childbirth; a pregnant person living with Hep B can pass Hep B to their newborn. • Having sex without a physical barrier, such as condoms or dental dams, with a person living with Hep B. • Sharing or reusing needles, medical or injection equipment, such as for insulin, glucose monitors, drug use, steroids, tattooing or acupuncture.
  • Making Hepatitis B History 2014 Annual Report

    Making Hepatitis B History 2014 Annual Report

    Making Hepatitis B History 2014 Annual Report BARUCH S. BLUMBERG INSTITUTE Hepatitis B Foundation 2014 Annual Report 1 Making Hepatitis B History December 2014 The next three years will be the “make-it” period for the Hepatitis B Foundation and its research arm, the Baruch S. Blumberg Institute. We have imposed an ambitious timeline for results because we believe the opportunity is now, and the need is urgent. Our world-class research institute—renamed in 2013 as the Baruch S. Blumberg Institute in honor of our co-founder and Nobel Laureate Dr. Blumberg—is poised to significantly accelerate the pace of research. We have recruited a group of first class scientists to join us fulltime at the Blumberg Institute in 2015. Our new scientists, however, aren’t starting from zero. Indeed, they will have a head start since we have been preparing and building toward this goal for more than two decades. And all of our scientists have pledged to identify breakthrough therapies for hepatitis B in the next three years. We want, and plan for, our discoveries to go from the lab into human use as quickly as possible. We know that this will require drug development experts with pharmaceutical company experience and we have already made arrangements to create technology development partnerships. This means that our scientists can focus on pioneering discoveries and our partners can carry them all the way to the clinic. Our hope for the next 5 to 10 years is simple—that a complete cure is found, which will benefit everyone living with chronic hepatitis B worldwide.
  • Needs of Individuals Living with Hepatitis Delta Virus and Their Caregivers, 2016-2019

    Needs of Individuals Living with Hepatitis Delta Virus and Their Caregivers, 2016-2019

    Thomas Jefferson University Jefferson Digital Commons Department of Medicine Faculty Papers Department of Medicine 12-17-2020 Needs of Individuals Living With Hepatitis Delta Virus and Their Caregivers, 2016-2019. Priyanka Kumar Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania; Jefferson College of Population Health, Philadelphia, Pennsylvania Catherine Freeland Jefferson College of Population Health, Philadelphia, Pennsylvania; Hepatitis B Foundation, Doylestown, Pennsylvania Sierra Bodor Hepatitis B Foundation, Doylestown, Pennsylvania Sean Farrell Jefferson College of Population Health, Philadelphia, Pennsylvania; Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania Follow this and additional works at: https://jdc.jefferson.edu/medfp Chari Par Cohent of the Other Medical Specialties Commons LetHepatitis us B Fknowoundation, how Doylest accessown, Pennsylv taniao this document benefits ouy RecommendedSee next page for Citation additional authors Kumar, Priyanka; Freeland, Catherine; Bodor, Sierra; Farrell, Sean; Cohen, Chari; and Frasso, Rosemary PhD, MSc, CPH, "Needs of Individuals Living With Hepatitis Delta Virus and Their Caregivers, 2016-2019." (2020). Department of Medicine Faculty Papers. Paper 284. https://jdc.jefferson.edu/medfp/284 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons.
  • Annual Report 2010

    Annual Report 2010

    2010 ANNUAL REPORT RESEARCH OUTREACH ADVOCACY 3 Hepat itis B Foundation “We appreciate [the HBF’s] continued support of the Hep B community. With the addition of a second adopted child DearThe Hepatitis Friends, B Foundation has enjoyed one of its most with hep B into our family, we obviously 2010 Annual Report productive years despite the economic downturn. We are are supportive of your efforts in pleased to report that our work has been a bright spot in RESEARCH research and education.” one of the toughest years. YEAR IN REVIEW (New Jersey) This year we have focused our efforts on making the FINANCIAL INFORMatioN* greatest impact on some of the greatest unmet needs. (Fiscal Year 2010 ending June 30, 2010) IN THE LABS This includes establishing consensus recommendations Sources of Funds – HBF & IHVR Combined for hepatitis B screening and treatment of children who (Total $4,322,068) live with this disease and for primary care providers who Charitable lack clear guidelines. Grants 84% Contributions 11% $3,649,257 $475,492 Research results take longer, but we have impressive Interest >1% LIVING SCIENCE and tangible results to share, too. This year, the liver $3,157 Building for a Cure cancer biomarker that we helped to discover has been Other 4% $194,162 HBF’s groundbreaking for the expansion optioned to a major diagnostics company. If all goes well, of its research facility to build nine new this blood test will be available for human use within the labs, which includes a teaching lab, • Biomarkers of liver cancer enter next couple of years.
  • Eliminating Hepatitis B in Asian American, Native Hawaiian, and Pacific Islander Communities

    Eliminating Hepatitis B in Asian American, Native Hawaiian, and Pacific Islander Communities

    Eliminating Hepatitis B in Asian American, Native Hawaiian, and Pacific Islander Communities Chari Cohen, DrPH, MPH FDA Office of Minority Kate Moraras, MPH Health and Health Equity Hepatitis B Foundation May 26, 2020 Learning Objectives 1. Recognize the health disparities associated with hepatitis B and liver cancer and describe the impact on Asian American, Native Hawaiian, and Pacific Islander communities. 2. Understand the challenges and barriers to hepatitis B screening and care among highly affected, underserved communities in the U.S. 3. Design and replicate innovative, multi-level strategies to eliminate hepatitis B-related health disparities among Asian American, Native Hawaiian, and Pacific Islander communities. Eliminating Hepatitis B in AAPI Communities ❑Hepatitis B Virus ❑Hepatitis B-Related Health Disparities ❑Hepatitis B and Liver Cancer ❑ Barriers to Screening & Treatment ❑ HBV-Related Stigma & Discrimination ❑Strategies to Eliminate Disparities ❑ Resources The Hepatitis B Virus •Hepatitis B is the world’s most common, serious liver infection in the world •Transmission: direct blood contact; sexual transmission; from mother to child (most common route worldwide) •Chronic HBV can lead to premature death from cirrhosis, liver failure and liver cancer •The Good News: we have safe and effective vaccines (2 or 3 doses) that offers life-long protection! Hepatitis B Global Epidemiology Almost 300 people worldwide are chronically infected 884,000 people die each year from HBV-related liver disease Razavi-Shearer et al. (2018). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology;;3(6):383-403. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017.
  • Ad Hoc Group for Medical Research FY 2021 Recommendation

    Ad Hoc Group for Medical Research FY 2021 Recommendation

    THE AD HOC GROUP FOR MEDICAL RESEARCH The Ad Hoc Group Fiscal Year (FY) 2021 Recommendation The 338 undersigned members of the Ad Hoc Group for Medical Research, which represents patient groups, scientific societies, research institutions, health professionals, educators, and industry, are extremely grateful to Congress for making meaningful, reliable funding support for the National Institutes of Health (NIH) a key national priority. NIH-funded research not only has improved our understanding of the fundamental life and health sciences but also has facilitated development of ever-evolving diagnostic and therapeutic advances. As a result, our ability to prevent, detect, diagnose, and treat diseases has increased dramatically over time. As a result of the strong, bipartisan vision of Senate and House Labor-HHS-Education Appropriations Subcommittee leaders Senators Roy Blunt and Patty Murray, and Representatives Rosa DeLauro and Tom Cole, over the last five years, Congress has helped the agency regain some of the ground lost after years of effectively flat budgets. This most welcome renewed investment in NIH has increased the pace of biomedical research, reenergized existing and aspiring scientists nationwide, and restored hope for patients and their families. Today, more than ever before, we are on the cusp of profound new advances in science and medicine, such as cancer immunotherapies and gene-editing tools. These discoveries can help solve some of our greatest health challenges and hold great potential to yield treatments for devastating diseases that currently have none. To further realize the potential of medical research, we must continue this forward momentum. For FY 2021, the Ad Hoc Group recommends $44.7 billion for the NIH, a $3 billion increase over NIH’s program level funding in FY 2020.
  • The Impact of Nail Salon Industry Policies and Regulations on Hepatitis B Awareness and Prevention

    The Impact of Nail Salon Industry Policies and Regulations on Hepatitis B Awareness and Prevention

    THE IMPACT OF NAIL SALON INDUSTRY POLICIES AND REGULATIONS ON HEPATITIS B AWARENESS AND PREVENTION HEPATITIS B FOUNDATION Hepatitis B Foundation 0 About the Author Eugene Ng was a Healthy Equity Fellow from the U.S. Department of Health and Human Services Office of Minority Health and worked with the Hepatitis B Foundation (HBF) in the summer of 2018. He has since continued to work with the Hepatitis B Foundation and their Public Health team. During his time with HBF, he conducted research on the landscape of the nail salon industry to better understand how industry regulations and policies affect hepatitis B education, awareness, and prevention. His work in the field of hepatitis B began under the guidance of Dr. Su Wang at the Center for Asian Health at Saint Barnabas Medical Center in Florham Park, NJ, where he was involved in outreach efforts to promote hepatitis B education, awareness, and prevention. Eugene completed his Bachelor of Science degree in genetics at the University of Minnesota and is currently pursuing a Medical Degree at the University of Colorado School of Medicine. Acknowledgements We sincerely thank our contributors from partner organizations and other institutions that offered their time and expertise to assemble this report. Contributing Partners Asian Pacific Health Foundation and Stakeholders California Healthy Nail Salon Collaborative Charles B. Wang Community Health Center Drexel University HOPE Clinic San Francisco Hep B Free – Bay Area Tacoma-Pierce County Health Department Hepatitis B Foundation Staff Chari Cohen, DrPH, MPH Kate Moraras, MPH Rhea Racho, MPAff Catherine Freeland, MPH Michaela Jackson, MS Maureen Kamischke Jenny Kimbel Sierra Pellechio, CHES Hepatitis B Foundation 1 Introduction major routes of transmission, for example, through unprotected sex or the sharing of razors or similar The hepatitis B virus (HBV) is the world’s most objects.
  • Biology Opportunities: Research, Co-Ops, Internships, Volunteer

    Biology Opportunities: Research, Co-Ops, Internships, Volunteer

    Biology Opportunities: Research, Co-ops, Internships, Volunteer Pennsylvania: Albert Einstein College of Medicine, Philadelphia, PA, Summer Undergraduate Research Program Bayer Crop Science, various locations - Select Student from scroll down Career Level under Job Search at top of right side column - review details for any intern positions listed, including location Beckman Coulter, various locations - enter Internship in Keywords box, then select R&D Biomedical Engineering Internship Becton, Dickinson and Company, several locations - enter Internship in Search by Keyword box Children's Hospital of Philadelphia Research Institute, Philadelphia, PA, Research Institute Children’s Hospital of Philadelphia, Philadelphia, PA, College Volunteer Program Children's Hospital of Pittsburgh, Pittsburgh, PA, Student Research Training Program Crozer-Keystone Health System, Upland, PA, Volunteer Programs Drexel University College of Medicine, Philadelphia, PA, Summer Undergraduate Research Fellowship Fox Chase Cancer Center, Philadelphia, PA, Undergraduate Summer Research Fellowship Genzyme Corp, locations in MA, NJ, PA, select Search Internships & Co-Op positions GlaxoSmithKline, Research Triangle Park, NC; Philadelphia, PA and other sites, application Internship and Co-op Program Hawk Mountain Sanctuary, Kempton, PA, Hepatitis B Foundation, Doylestown, PA, College Summer Research Internship Program Hospital of the University of Pennsylvania, Philadelphia, PA, College Volunteer Program Lankenau Institute for Medical Research, Wynnewood, PA Lehigh

  • Prevalence of Hepatitis B Infection Among African Immigrants in the Greater Philadelphia Area Monisola Abike Obikoya-Malomo June

    Prevalence of Hepatitis B Infection among African Immigrants in the Greater Philadelphia Area Monisola Abike Obikoya-Malomo June, 2012 A Community Based Master’s Project presented to the faculty of Drexel University School of Public Health in partial fulfillment of the Requirement for the Degree of Master of Public Health ii ACKNOWLEDGEMENTS First, I would like to thank almighty God for making this possible, for without Him; the story would have been different. I also want to thank my faculty advisor for his exceptional excellent mentorship, Professor Edward J. Gracely, my preceptor, Ms. Chari Cohen for her guidance and support throughout this process. I also want to thank my husband, Olukayode Malomo and our wonderful sons, Ooreofeoluwa and Oreoluwa for being so supportive and understanding. I also want to thank every member of my family and my in-laws and friends for their words of encouragement. My thanks go to Ms. Tope Owolabi for taking care of my children while I was busy studying. My sincere thanks to every faculty member in the School of Public Health that has impacted in me the wealth of knowledge that I need to succeed in the real world. I would also like to thank the CBMP faculty chair, Prof. Craig J. Newschaffer, Prof Alison A. Evans, Prof. Dennis Gallagher for their support and kind assistance always. I would especially like to thank Hepatitis B Foundation for allowing me make use of their data, their staff members that had worked tirelessly with the African immigrant community and all participants that have been part of this project with the Hepatitis B Foundation.

  • The Role and Impact of Patient and Advocacy Groups in and Outside Europe, Held on March 12-14, 2008 in Lucca, Italy

    VIRAL HEPATITIS Published by the Viral Hepatitis Prevention Board (VHPB) November 2008 Editorial Volume 17 - Number 1 This issue of Viral Hepatitis reviews topics covered at the Viral Hepatitis Prevention Board CONTENTS (VHPB)/European Liver Patient Association’s (ELPA) spring meeting on the Prevention and EDITORIAL . 1 control of viral hepatitis: the role and impact of patient and advocacy groups in and outside Europe, held on March 12-14, 2008 in Lucca, Italy . Role and impact of umbrella organizations 2 The meeting brought together 12 national patient organizations from Europe and the United European Liver Patients Association (ELPA) . 2 States, 3 umbrella organizations and one organization representing the interests of the Asian/ European patient groups for rare diseases (EURORDIS) . 3 Pacific Islander American community, with the aim of providing an overview of the activities, role, rationale and impact of international and national patient and advocacy groups in Europe National Viral Hepatitis Roundtable (NVHR) . 3 and the United States in terms of prevention and control of viral hepatitis . European Federation of Pharmaceutical industries and associations (EFPIA) ethical code . 4 The diversity of participating patient organizations to this forum favoured productive cross- fertilization, in particular in terms of objectives, functioning structure, financial resources and Wide-reaching initiatives to get attention and increase awareness on prevention of viral efficient targeted programs and actions. Hence, it created an opportunity for them to share hepatitis . 5 experiences on their activities, as well as identifying their strengths and weaknesses, together European Immunization Week (EIW) . 5 with challenges and thresholds regarding their role and impact on prevention and control of World Hepatitis Day (WHD) .
  • Summer 2018 Issue

    Summer 2018 Issue

    HepB.org Informed 73 THE NEWSLETTER OF THE HEPATITIS B FOUNDATION Summer 2018 Inside this issue 2 Two-Dose Hepatitis B Vaccine Approved 3 Partnering to End Hepatitis B in Vietnam Hepatitis B Foundation Calls for 5 New #justB Stories Released 8 Dr. Tim Block Named Fellow of UNIVERSAL SCREENING National Academy of Inventors for Hepatitis B page 6 All Americans should know their status to eliminate public health threat 2018 Crystal Ball Gala In recognition of World Hepatitis Day in July, the Hepatitis B Foundation has called for all Americans to be tested for hepatitis B infection. The formal recommendation was approved by HBF’s Scientific and Medical Advisory Board to achieve the World Health Organization’s (WHO) ambitious goal of eliminating hepatitis B by the year 2030. Up to 2.2 million Americans, and Timothy Block, PhD, President of the challenges, including the complexity more than 292 million people worldwide, Hepatitis B Foundation and its Baruch S. of risk-based screening, and stigma are chronically infected with Blumberg Institute. “Current guidelines surrounding hepatitis B, have led to a lack 2.2 this serious virus of the liver, recommend testing for people in high risk of adherence of the current guidelines, million which can lead to cirrhosis populations, but data suggests that up to Americans infected and liver cancer. Because 40% of those infected may not fall within increase in hepatitis B testing in the U.S. there are often few symptoms, those populations. It is imperative that we andHBF’s there recommendationhas not been a significant is limited 292 hepatitis B frequently goes test everyone in order to provide care and to adults, because universal infant million undiagnosed, with experts education that will reduce deaths from vaccination has been standard in the U.S.
  • Fall 2018 Issue

    Fall 2018 Issue

    HepB.org Informed 74 THE NEWSLETTER OF THE HEPATITIS B FOUNDATION Fall 2018 Inside this issue Hepatitis B Foundation Launching 2 3 HepNew B Vice Cure Presidents Campaign Named Effort to IMPROVE Patient Access Grows Momentum to Hepatitis B Medications 5 Hepatitis B Foundation to Provide Resources for African 5 Immigrant Communities 7 Focus on Hepatitis Delta or many people with chronic hepatitis B, Provider Profile: Dr. Su Wang Fthe cost of antiviral medications is a major barrier to treatment. Even those who have prescription coverage can face co-pays that put page 6 medication out of reach. 6th Hep B United Summit While U.S. health insurance through “adverse tiering” to discourage plans must cover people living with Florida’s 2018 healthcare marketplace. hepatitis B, many plans place hepatitis OurQualified research Health revealed Plans thatsold commonthrough their plans. The complaint was based B medications in a category that hepatitis B medications were placed on people living with HIV from buying dramatically increases the co-pays for the highest two tiers in the majority of available in 2014 and 2015, and found those drugs. Although current laws the plans. These tiers typically required thaton Florida four of Qualified the insurance Health plans Plans they protect individuals with pre-existing patients to meet deductibles between conditions including hepatitis B, from $2,500 and $6,750 before allowing highest tier, leading to inordinately discriminatory practices by health highreviewed co-payments placed all and HIV co-insurance drugs on the for insurance companies, these prescription drugs, even generics. This over-pricing medications used in the treatment of pricing practices have effectively made ofcost-sharing certain drugs benefits by placing for any them hepatitis in a B many insurance plans unaffordable for higher tier, called “adverse tiering,” acts people living with hepatitis B.